Atyr PHARMA (NASDAQ:ATYR) Now Covered by Analysts at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage on shares of Atyr PHARMA (NASDAQ:ATYR) in a research report report published on Monday morning, Marketbeat.com reports. The firm issued an overweight rating on the stock.

ATYR has been the subject of several other reports. Wells Fargo & Company initiated coverage on shares of Atyr PHARMA in a research report on Friday, October 4th. They issued an “overweight” rating and a $17.00 target price for the company. HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective on shares of Atyr PHARMA in a report on Tuesday, December 10th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Atyr PHARMA presently has a consensus rating of “Buy” and a consensus target price of $19.25.

Atyr PHARMA Trading Down 0.3 %

Shares of ATYR opened at $3.97 on Monday. Atyr PHARMA has a 12-month low of $1.39 and a 12-month high of $4.23. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02. The company has a market cap of $333.25 million, a P/E ratio of -4.22 and a beta of 1.08. The firm’s 50-day simple moving average is $3.30.

Atyr PHARMA (NASDAQ:ATYR) last announced its earnings results on Thursday, November 7th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.01). As a group, analysts predict that Atyr PHARMA will post -0.89 earnings per share for the current year.

Hedge Funds Weigh In On Atyr PHARMA

An institutional investor recently raised its position in Atyr PHARMA stock. JPMorgan Chase & Co. boosted its stake in Atyr PHARMA INC (NASDAQ:ATYR) by 52.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 31,440 shares of the company’s stock after purchasing an additional 10,754 shares during the period. JPMorgan Chase & Co.’s holdings in Atyr PHARMA were worth $55,000 at the end of the most recent reporting period. 61.72% of the stock is owned by hedge funds and other institutional investors.

Atyr PHARMA Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.